Efgartigimod治疗全身型重症肌无力的ADAPT三期试验
ADAPT是一项随机双盲安慰剂对照三期试验,纳入167例全身型重症肌无力患者,评估efgartigimod(10 mg/kg)的安全性和疗效。Efgartigimod耐受性良好,最常见不良事件为头痛和鼻咽炎。
要点
- Efgartigimod显著提高AChR抗体阳性gMG患者第一周期MG-ADL应答率(68% vs 30%)。
- Efgartigimod耐受性良好,治疗中出现的不良事件与安慰剂组相近。
- 基于临床反应的个体化给药方案是ADAPT试验的独特设计。
核心结论
- Efgartigimod在全身型重症肌无力患者中耐受性良好且有效。
研究设计与样本
- ADAPT为随机、双盲、安慰剂对照三期试验,在15个国家56个神经肌肉中心进行。
- 纳入167例≥18岁全身型重症肌无力患者,随机1:1接受efgartigimod 10 mg/kg或安慰剂,每周期4次输注(每周1次),根据临床反应可按需重复(不早于前一周期开始后8周)。
- 主要终点为第一治疗周期乙酰胆碱受体抗体阳性患者中MG-ADL应答者比例(MG-ADL改善≥2分持续≥4周)。
主要发现
- Efgartigimod组65/84(77%)和安慰剂组70/83(84%)发生治疗中出现的不良事件。
- 最常见不良事件为头痛(efgartigimod 24/84 [29%] vs 安慰剂 23/83 [28%])和鼻咽炎(efgartigimod 10/84 [12%] vs 安慰剂 15/83 [18%])。
- 严重不良事件:efgartigimod组4/84(5%),安慰剂组7/83(8%);每组各3例(4%)中止治疗;无死亡。
关键数值与推荐
- MG-ADL应答定义为MG-ADL评分改善≥2分且持续≥4周。
- 入组要求MG-ADL评分≥5分(>50%为非眼部症状),且至少一种gMG治疗剂量稳定。
临床怎么用
- Efgartigimod可作为AChR抗体阳性全身型重症肌无力的靶向治疗选择,基于临床反应个体化给药。
- 治疗期间需监测头痛和鼻咽炎等不良事件。
局限性
- 主要终点仅分析AChR抗体阳性患者,非抗体阳性人群数据有限。
- 长期安全性和有效性需待正在进行的开放标签扩展研究(ADAPT+)进一步提供。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an unmet need for treatment options for generalised myasthenia gravis that are effective, targeted, well tolerated, and can be used in a broad population of patients. We aimed to assess the safety and efficacy of efgartigimod (ARGX-113), a human IgG1 antibody Fc fragment engineered to reduce pathogenic IgG autoantibody levels, in patients with generalised myasthenia gravis. METHODS: ADAPT was a randomised, double-blind, placebo-controlled, phase 3 trial done at 56 neuromuscular academic and community centres in 15 countries in North America, Europe, and Japan. Patients aged at least 18 years with generalised myasthenia gravis were eligible to participate in the study, regardless of anti-acetylcholine receptor antibody status, if they had a Myasthenia Gravis Activities of Daily Living (MG-ADL) score of at least 5 (>50% non-ocular), and were on a stable dose of at least one treatment for generalised myasthenia gravis. Patients were randomly assigned by interactive response technology (1:1) to efgartigimod (10 mg/kg) or matching placebo, administered as four infusions per cycle (one infusion per week), repeated as needed depending on clinical response no sooner than 8 weeks after initiation of the previous cycle. Patients, investigators, and clinical site staff were all masked to treatment allocation. The primary endpoint was proportion of acetylcholine receptor antibody-positive patients who were MG-ADL responders (≥2-point MG-ADL improvement sustained for ≥4 weeks) in the first treatment cycle. The primary analysis was done in the modified intention-to-treat population of all acetylcholine receptor antibody-positive patients who had a valid baseline MG-ADL assessment and at least one post-baseline MG-ADL assessment. The safety analysis included all randomly assigned patients who received at least one dose or part dose of efgartigimod or placebo. This trial is registered at ClinicalTrials.gov (NCT03669588); an open-label extension is ongoing (ADAPT+, NCT03770403). FINDINGS: Between Sept 5, 2018, and Nov 26, 2019, 167 patients (84 in the efgartigimod group and 83 in the placebo group) were enrolled, randomly assigned, and treated. 129 (77%) were acetylcholine receptor antibody-positive. Of these patients, more of those in the efgartigimod group were MG-ADL responders (44 [68%] of 65) in cycle 1 than in the placebo group (19 [30%] of 64), with an odds ratio of 4·95 (95% CI 2·21-11·53, p<0·0001). 65 (77%) of 84 patients in the efgartigimod group and 70 (84%) of 83 in the placebo group had treatment-emergent adverse events, with the most frequent being headache (efgartigimod 24 [29%] vs placebo 23 [28%]) and nasopharyngitis (efgartigimod ten [12%] vs placebo 15 [18%]). Four (5%) efgartigimod-treated patients and seven (8%) patients in the placebo group had a serious adverse event. Three patients in each treatment group (4%) discontinued treatment during the study. There were no deaths. INTERPRETATION: Efgartigimod was well tolerated and efficacious in patients with generalised myasthenia gravis. The individualised dosing based on clinical response was a unique feature of ADAPT, and translation to clinical practice with longer term safety and efficacy data will be further informed by the ongoing open-label extension. FUNDING: argenx.
引用
- Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021. PMID: 34146511. doi:10.1016/S1474-4422(21)00159-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。